[go: up one dir, main page]

WO2007009529A2 - Composante peptide de calcium - Google Patents

Composante peptide de calcium Download PDF

Info

Publication number
WO2007009529A2
WO2007009529A2 PCT/EP2006/005173 EP2006005173W WO2007009529A2 WO 2007009529 A2 WO2007009529 A2 WO 2007009529A2 EP 2006005173 W EP2006005173 W EP 2006005173W WO 2007009529 A2 WO2007009529 A2 WO 2007009529A2
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
peptide component
preparation
agent
glycomacropeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/005173
Other languages
German (de)
English (en)
Other versions
WO2007009529A3 (fr
Inventor
Marco Sell
Dirk Bode
Günther Sawatzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HUMANA GmbH
Original Assignee
HUMANA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUMANA GmbH filed Critical HUMANA GmbH
Priority to EP06754001A priority Critical patent/EP1903895A2/fr
Priority to EA200800205A priority patent/EA016259B1/ru
Publication of WO2007009529A2 publication Critical patent/WO2007009529A2/fr
Publication of WO2007009529A3 publication Critical patent/WO2007009529A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to a calcium-peptide component and their use Phyg.
  • Calcium may have a palliative effect on depression, anxiety, and mood disorders associated with the premenstrual syndrome (S. Thys-Jacobs, J Amer Coli Nutr 19, 220-227 (2000); ER Bertone Johnson et al., Arch Intern Med , 1246-52 (2005))
  • S. Thys-Jacobs J Amer Coli Nutr 19, 220-227 (2000); ER Bertone Johnson et al., Arch Intern Med , 1246-52 (2005)
  • milk is the most important source of calcium.
  • the consumption of milk has declined significantly in recent years as so-called cow's milk intolerance has increasingly increased in the Central European population.
  • other dairy products can be used instead of milk, but consumers' consumption habits are often still in conflict. Because of this, calcium is added to foods that do not normally contain it.
  • the object of the invention is therefore to develop a source of calcium for products that provide calcium in a soluble form.
  • a calcium-peptide component of the aforementioned type which contains at least one calcium salt, cagedophosphopeptides and glycomacropeptide.
  • Amount of calcium in proteins It is known from milk that the calcium is evenly distributed in the liquid and not at the bottom in the form of sediment is deposited.
  • the calcium in the milk is mainly bound to the so-called caseins, a part of the milk proteins.
  • the caseins have the disadvantage of precipitating in the acid so that the bound casein calcium is unsuitable for acidic products.
  • caseinophosphopeptides which bind calcium particularly well.
  • Such caseinophosphopeptides are commercially available today (eg CPP DMV). Through the use of caseinophosphopeptides, it is now possible to achieve largely clear calcium solutions.
  • glycomacropeptide In the production of cheese, the action of the rennet casein releases the glycomacropeptide. This glycomacropeptide is located after cheese production in the so-called whey fraction.
  • the glycomacropeptide is a fragment of ⁇ -casein with the amino acid
  • Glycomacropeptide also contains a phosphate group which can bind calcium to itself.
  • the weight ratio between the calcium salts, caseinophosphopeptide and glycomacropeptide is preferably 1 - 5: 0.5 - 2.5: 1.5 - 7.5. Furthermore, the addition of minerals and / or trace elements is conceivable. In order to avoid problems of deposition of calcium in the blood vessels, magnesium may additionally be added to the calcium-peptide component according to the invention. All magnesium salts permitted under the food law can be added. The daily amount recommended is a maximum of 250 mg of magnesium.
  • vitamins are also added; especially vitamin D, which is responsible for the absorption of calcium in the small intestine.
  • soluble fiber such as oligofructose or galactooligosaccharides, and / or phytosterols is a preferred embodiment of the component according to the invention.
  • Suitable calcium salts are all food-approved salts. Here are some to name: calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium, calcium orthophosphate, calcium oxide and / or calcium hydroxide.
  • the calcium-peptide component according to the invention has a weight-reducing property in animal experiments.
  • rats for example, a lower weight gain and significantly lower fat gain could be recorded.
  • the same effect could also be demonstrated in patients complaining of weight problems.
  • Another invention therefore also relates to the use of the calcium-peptide component according to the invention as a medicament, for the preparation of an agent for regulating body weight or for improving calcium absorption. Moreover, the invention relates to the use of the calcium-peptide component for the preparation of an agent for regulating blood pressure and for producing an agent for alleviating the symptoms of premenstrual syndrome.
  • the invention also relates to the use of the three main components calcium salts, caseinophosphopeptides and glycomacropeptides for the preparation of preparations for weight reduction.
  • the calcium-peptide component according to the invention can be offered both as additives in foods, as a dietary supplement or as a pharmaceutical preparation.
  • the calcium-peptide component according to the invention is versatile, in particular imaginable as candy, powder, tablets, compacted forms, bars, jellies or emulsions.
  • Typical application examples are the use in fruit juices, quark and yoghurt foods, whey drinks, desserts, ice cream, calcium tablets or fruit jars.
  • the calcium-peptide component according to the invention can be composed as follows (the recommended daily dose is given as an example):

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une composante peptide de calcium qui peut être obtenue à partir de: au moins un sel de calcium; un phosphopeptide de caséine et un glycomacropeptide. Il est ainsi possible de se servir du principe du lait selon lequel des quantités importantes du calcium se lient à des protéines.
PCT/EP2006/005173 2005-07-19 2006-05-31 Composante peptide de calcium Ceased WO2007009529A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06754001A EP1903895A2 (fr) 2005-07-19 2006-05-31 Composante peptide de calcium
EA200800205A EA016259B1 (ru) 2005-07-19 2006-05-31 Применение кальций-пептидного компонента для снижения веса тела

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005033630A DE102005033630A1 (de) 2005-07-19 2005-07-19 Calcium-Peptid-Komponente
DE102005033630.2 2005-07-19

Publications (2)

Publication Number Publication Date
WO2007009529A2 true WO2007009529A2 (fr) 2007-01-25
WO2007009529A3 WO2007009529A3 (fr) 2007-06-28

Family

ID=37575596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005173 Ceased WO2007009529A2 (fr) 2005-07-19 2006-05-31 Composante peptide de calcium

Country Status (5)

Country Link
EP (1) EP1903895A2 (fr)
DE (1) DE102005033630A1 (fr)
EA (1) EA016259B1 (fr)
UA (1) UA94716C2 (fr)
WO (1) WO2007009529A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055801A3 (fr) * 2006-11-06 2008-12-04 Humana Milchunion Eg Composition calcium-peptide anti-diabétogène
WO2011137249A1 (fr) * 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Formulations prébiotiques et méthodes d'utilisation
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
CN109805417A (zh) * 2019-03-01 2019-05-28 河南九九一生物科技有限公司 一种能够增加骨密度的保健食品及其加工方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007022694A1 (de) 2007-05-11 2008-11-13 Humana Milchunion Eg Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
CN103445045A (zh) * 2012-05-30 2013-12-18 孔徐生 一种具有促进钙吸收功能的组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3373544B2 (ja) * 1991-12-05 2003-02-04 明治乳業株式会社 月経困難症を緩和する効果のある、カルシウム利用性に優れた飲食品及び医薬品
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
PL358423A1 (en) * 2000-04-18 2004-08-09 Societe Des Produits Nestle S.A. Nutritional modules
US6384087B1 (en) * 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
GB0100273D0 (en) * 2001-01-08 2001-02-14 Nestle Sa Nutritional composition for a bone condition
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
JP2003048843A (ja) * 2002-07-17 2003-02-21 Meiji Milk Prod Co Ltd 月経困難症の予防及び／又は治療用機能性食品

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
WO2008055801A3 (fr) * 2006-11-06 2008-12-04 Humana Milchunion Eg Composition calcium-peptide anti-diabétogène
EA016545B1 (ru) * 2006-11-06 2012-05-30 Хумана Мильхунион Эг Применение кальций-пептидной композиции для профилактики и/или лечения сахарного диабета ii типа
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9579340B2 (en) 2009-02-24 2017-02-28 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9592248B2 (en) 2009-02-24 2017-03-14 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9775860B2 (en) 2009-02-24 2017-10-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9808481B2 (en) 2009-02-24 2017-11-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2011137249A1 (fr) * 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Formulations prébiotiques et méthodes d'utilisation
CN109805417A (zh) * 2019-03-01 2019-05-28 河南九九一生物科技有限公司 一种能够增加骨密度的保健食品及其加工方法

Also Published As

Publication number Publication date
DE102005033630A1 (de) 2007-01-25
WO2007009529A3 (fr) 2007-06-28
EP1903895A2 (fr) 2008-04-02
EA200800205A1 (ru) 2008-08-29
UA94716C2 (ru) 2011-06-10
EA016259B1 (ru) 2012-03-30

Similar Documents

Publication Publication Date Title
DE60310934T2 (de) Zusammensetzung, die ein sättigungsgefühl hervorruft
DE69732871T2 (de) Basisches Protein Zusammensetzung, basisches Peptid Zusammensetzung und deren Verwendung
DE69233250T2 (de) Kombinationen aus calzium und vitamin d
DE60126104T2 (de) Ernährungszusammensetzung und verfahren zur verbesserung der absetzung von proteinen
DE60122570T2 (de) Nahrungszusammensetzung für immunerkrankung
EP2114174B1 (fr) Utilisation (de sels) d'acide guanidinoacétique en association avec de la bétaïne et/ou de la choline pour produire un agent bénéfique pour la santé
CN111616232A (zh) 一种促进骨骼生长的儿童奶粉及其制备方法
EP2680713B1 (fr) Composition à usage nutritionnel
AU2002221860A1 (en) Nutritional composition for an immune condition
JP2001158736A (ja) 骨関節疾患の予防及び改善剤
TW201036618A (en) Nutritional composition for controlling blood sugar level
WO2008138821A1 (fr) Composition à base de matière grasse lactique et de protéine lactique (de préférence, estérifiée par l'acide palmitique) destinée à l'amélioration de l'absorption du calcium
DE69922409T2 (de) Verwendung von natürlichen antisekretorischen Proteinen
EP1903895A2 (fr) Composante peptide de calcium
EP2996710B1 (fr) Substance active pour le traitement de la sarcopénie
WO2010061877A1 (fr) Améliorant d’absorption de minéraux, et procédé pour améliorer l’absorption de minéraux
DE20300380U1 (de) Speiseeis
WO2005097146A2 (fr) Composantes laitieres utiles pour la perte de tissu adipeux
NL9401958A (nl) Met eierschalenmeel verrijkt melkprodukt.
AT10252U1 (de) Eiweisspräparat
EP1862197A2 (fr) Utilisation d'un concentré de protéines
EP2089046A2 (fr) Composition calcium-peptide anti-diabétogène
EP0374935B1 (fr) Préparation pour prévenir l'ostéoporose et pour traiter l'ostéoporose
JP3248170B2 (ja) コンドロイチン硫酸蛋白複合体含有食品
JPH1146720A (ja) カルシウム吸収促進栄養組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006754001

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200800205

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006754001

Country of ref document: EP